Stockscreener 앱 받기
20.56
0.58%
-0.12
Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스
SNDX Maintained by UBS -- Price Target Lowered to $33 - GuruFocus
UBS lowers Syndax Pharmaceuticals price target on revenue outlook By Investing.com - Investing.com Canada
Syndax (SNDX) Q2 2026 Earnings Call Transcript - AOL.com
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates - Eastern Progress
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet - Eastern Progress
Syndax (SNDX) Quarterly Results: Profit Per Share Falls Below Its Benchmark in the Reported Period; Trading Move - vinanet.vn
Exploring 3 High Growth Tech Stocks In The US Market - Sahm
Syndax Pharmaceuticals (SNDX) Edges Up 0.46% to $19.85 as Range-Bound Trading PersistsHigh Low Breadth - vinanet.vn
GSA Capital Partners LLP Purchases New Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Stifel Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
SNDX Stock Price, Quote & Chart - ChartMill
The Technical Signals Behind (SNDX) That Institutions Follow - Stock Traders Daily
Syndax (SNDX) Sales Nearly Doubled, So Why Did The Stock Fall? - Yahoo Finance
SNDX Maintained by JP Morgan -- Price Target Lowered to $40.00 - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $40.00 Price Target at JPMorgan Chase & Co. - MarketBeat
J.P. Morgan Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $40 - Moomoo
Syndax Pharmaceuticals (SNDX) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Hennion & Walsh Asset Management Inc. Increases Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Bank of America Corp DE Decreases Position in Syndax Pharmaceuticals, Inc. $SNDX - marketbeat.com
Net margin % of Syndax Pharmaceuticals Inc – HAM:1T3 - TradingView
Long term debt to total assets ratio of Syndax Pharmaceuticals Inc – HAM:1T3 - TradingView
Total common shares outstanding of Syndax Pharmaceuticals Inc – HAM:1T3 - TradingView
Price to sales forward of Syndax Pharmaceuticals Inc – HAM:1T3 - TradingView
State Street Corporation (SNDX) discloses 5.66M-share, 6.4% holding in Syndax - Stock Titan
How Surging Revuforj and Niktimvo Sales and Narrowing Losses Could Shape Syndax Pharmaceuticals (SNDX) Investors - Yahoo Finance
Syndax Pharmaceuticals Inc (1T3) Q3 2024 Earnings ReportResults, Call & Slides - tipranks.com
Earnings Update: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Just Reported And Analysts Are Trimming Their Forecasts - simplywall.st
HC Wainwright Brokers Decrease Earnings Estimates for SNDX - MarketBeat
Syndax Pharmaceuticals Inc (1T3) Q1 2024 Earnings ReportResults, Call & Slides - tipranks.com
Surging Revenue And Narrower Losses Might Change The Case For Investing In Syndax Pharmaceuticals (SNDX) - webull.com
What is HC Wainwright's Estimate for SNDX FY2029 Earnings? - MarketBeat
BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $26 - Moomoo
A Quick Look at Today's Ratings for Syndax Pharmaceuticals(SNDX.US), With a Forecast Between $26 to $57 - Moomoo
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Five New Syndax Employees Receive Stock Options With 4-Year Vesting - Stock Titan
Syndax Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:SNDX) 2026-08-05 - Seeking Alpha
Syndax Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $38.27, Implies 101% Upside - TradingView
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down on Disappointing Earnings - MarketBeat
SNDX Maintains Rating by HC Wainwright & Co. -- Price Target Low - GuruFocus
HC Wainwright Has Lowered Expectations for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - marketbeat.com
Sei Investments Co. Grows Stake in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) (Q2 2026) Earnings Call Highli - GuruFocus
SNDX Q2 2026 Sales Surge Highlights Growth Potential Despite Val - GuruFocus
Syndax Pharmaceuticals Inc (SNDX) (Q2 2026) Earnings Call Highlights: Revenue Surges 92% as ... - Yahoo! Finance Canada
SNDX SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Syndax Pharmaceuticals Q2 Earnings Call Highlights - marketbeat.com
Syndax Pharmaceuticals (SNDX) Q2 Revenue Miss Highlights Valuati - GuruFocus
Is Syndax Pharmaceuticals Inc (SNDX) Facing Value Challenges Aft - GuruFocus
SNDX: Q2 revenue surged 92% year-over-year, driven by strong Revuforj and Niktimvo growth - TradingView
Syndax Pharmaceuticals (NASDAQ:SNDX) Releases Quarterly Earnings Results - MarketBeat
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates - finance.yahoo.com
Syndax Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Q2 2026 Syndax Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
SNDX: Q2 2026 revenue jumped 92% YoY as losses narrowed and pipeline assets advanced - TradingView
Syndax: Q2 Earnings Snapshot - marketscreener.com
Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
SNDX Financials: Income Statement, Balance Sheet & Cash Flow | Syndax Pharmaceuticals Inc - Stock Titan
Syndax Pharmaceuticals | 10-Q: Q2 2026 Earnings Report - moomoo.com
Precision Trading with Syndax Pharmaceuticals Inc. (SNDX) Risk Zones - Stock Traders Daily
Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Healthcare of Ontario Pension Plan Trust Fund - MarketBeat
Bank of New York Mellon Corp Decreases Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals to Report Second Quarter 2026 Financial Results and Host Conference Call on August 4 - Quiver Quantitative
Syndax will give a cancer-therapy business update Aug. 4 - Stock Titan
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026 - GlobeNewswire
Syndax Pharmaceuticals, Inc. $SNDX is Eversept Partners LP's 6th Largest Position - MarketBeat
0.86%
0.31%
자본화:
|
볼륨(24시간):